Free tool
FAERS Monitor: Locametz
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215841 or its brand name (Locametz, Gallium Ga-68 Gozetotide). Reports on generic versions are filed under their own applications.
Reports
45
Serious
35
78% of reports
Hospitalization
25
Death reported
4
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- anaemia3
- alanine aminotransferase increased2
- bone marrow failure2
- dyspnoea2
- expired product administered2
- febrile neutropenia2
- pancytopenia2
- sciatica2
- skin infection2
- agitation1
- agranulocytosis1
- amylase increased1
- arthralgia1
- aspartate aminotransferase increased1
- aspiration1
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2022 | 7 |
| 2023 | 31 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 1 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,114 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| amylase increased | 1 | 126.7 | 18.2 | 31 |
| skin infection | 2 | 83.3 | 21.5 | 91 |
| sciatica | 2 | 58.7 | 15.1 | 63 |
| bone marrow failure | 2 | 46.0 | 11.9 | 49 |
| aspiration | 1 | 42.7 | 6.1 | 10 |
| expired product administered | 2 | 28.1 | 7.3 | 29 |
| agranulocytosis | 1 | 25.1 | 3.6 | 5 |
| pancytopenia | 2 | 16.7 | 4.3 | 16 |
| alanine aminotransferase increased | 2 | 15.2 | 3.9 | 14 |
| febrile neutropenia | 2 | 14.1 | 3.6 | 13 |
| aspartate aminotransferase increased | 1 | 8.8 | 1.3 | 1 |
| anaemiaSignal | 3 | 7.4 | 2.5 | 11 |
| agitation | 1 | 6.4 | 0.9 | 1 |
| dyspnoea | 2 | 1.7 | 0.4 | 0 |
| arthralgia | 1 | 1.1 | 0.2 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.